Base de dados : MEDLINE
Pesquisa : D23.050.161.386 [Categoria DeCS]
Referências encontradas : 479 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 48 ir para página                         

  1 / 479 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Araujo, Sergio
Texto completo SciELO Brasil
[PMID]:26676499
[Au] Autor:Araujo S; Rezende MM; Sousa DC; Rosa MR; Santos DC; Goulart LR; Goulart IM
[Ad] Endereço:Centro de Referência Nacional em Dermatologia Sanitária e Hanseníase, Hospital de Clínicas, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
[Ti] Título:Risk-benefit assessment of Bacillus Calmette-Guérin vaccination, anti-phenolic glycolipid I serology, and Mitsuda test response: 10-year follow-up of household contacts of leprosy patients.
[So] Source:Rev Soc Bras Med Trop;48(6):739-45, 2015 Nov-Dec.
[Is] ISSN:1678-9849
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Despite multidrug therapy, leprosy remains a public health issue. The intradermal Bacillus Calmette-Guérin (BCG) vaccine, Mitsuda test (lepromin skin test), and anti-phenolic glycolipid I (PGL-I) serology are widely used in leprosy studies and have shown great epidemiological value. METHODS: This longitudinal study evaluated the relative risks and benefits of these three tools by comparing results observed in household contacts (HHCs) of leprosy patients who developed leprosy with those of HHCs who did not in a population of 2,992 individuals monitored during a 10-year period. RESULTS: Seventy-five (2.5%) new leprosy cases were diagnosed, including 28 (0.9%) co-prevalent cases. Therefore, for the risk-benefit assessment, 47 (1.6%) HHCs were considered as truly diagnosed during follow-up. The comparison between healthy and affected contacts demonstrated that not only did BCG vaccination increase protection, but boosters also increased to 95% relative risk (RR) reduction when results for having two or more scars were compared with having no scars [RR, 0.0459; 95% confidence interval (CI), 0.006-0.338]. Similarly, Mitsuda reactions >7mm in induration presented 7-fold greater protection against disease development compared to reactions of 0-3mm (RR, 0.1446; 95% CI, 0.0566-0.3696). In contrast, anti-PGL-I ELISA seropositivity indicated a 5-fold RR increase for disease outcome (RR, 5.688; 95% CI, 3.2412-9.9824). The combined effect of no BCG scars, Mitsuda reaction of <7mm, and seropositivity to anti-PGL-I increased the risk for leprosy onset 8-fold (RR, 8.109; 95% CI, 5.1167-12.8511). CONCLUSIONS: The adoption of these combined assays may impose measures for leprosy control strategies.
[Mh] Termos MeSH primário: Antígenos de Bactérias/imunologia
Vacina BCG/imunologia
Busca de Comunicante/estatística & dados numéricos
Glicolipídeos/imunologia
Hanseníase/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Criança
Pré-Escolar
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Lactente
Recém-Nascido
Antígeno de Mitsuda/imunologia
Hanseníase/prevenção & controle
Hanseníase/transmissão
Estudos Longitudinais
Masculino
Meia-Idade
Medição de Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, Bacterial); 0 (BCG Vaccine); 0 (Glycolipids); 0 (phenolic glycolipid I, Mycobacterium leprae); 11006-67-0 (Lepromin)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:151217
[Lr] Data última revisão:
151217
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151218
[St] Status:MEDLINE


  2 / 479 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23870850
[Au] Autor:Eichelmann K; González González SE; Salas-Alanis JC; Ocampo-Candiani J
[Ad] Endereço:Servicio de Dermatología, Hospital Universitario José Eleuterio González, Monterrey Nuevo León, Mexico. eichelmannk@gmail.com
[Ti] Título:Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment.
[So] Source:Actas Dermosifiliogr;104(7):554-63, 2013 Sep.
[Is] ISSN:1578-2190
[Cp] País de publicação:Spain
[La] Idioma:eng
[Ab] Resumo:Leprosy is a chronic granulomatous disease caused by the bacillus Mycobacterium leprae. It primarily affects the skin and peripheral nerves and is still endemic in various regions of the world. Clinical presentation depends on the patient's immune status at the time of infection and during the course of the disease. Leprosy is associated with disability and marginalization. Diagnosis is clinical and is made when the patient has at least 1 of the following cardinal signs specified by the World Health Organization: hypopigmented or erythematous macules with sensory loss; thickened peripheral nerves; or positive acid-fast skin smear or skin biopsy with loss of adnexa at affected sites. Leprosy is treated with a multidrug combination of rifampicin, clofazimine, and dapsone. Two main regimens are used depending on whether the patient has paucibacillary or multibacillary disease.
[Mh] Termos MeSH primário: Hanseníase
[Mh] Termos MeSH secundário: Anticorpos Antibacterianos/sangue
Anticorpos Antibacterianos/imunologia
Antígenos de Bactérias/imunologia
Vacina BCG
Vacinas Bacterianas
Quimioterapia Combinada
Saúde Global
Glicolipídeos/imunologia
Seres Humanos
Testes Intradérmicos
Antígeno de Mitsuda
Hansenostáticos/administração & dosagem
Hansenostáticos/efeitos adversos
Hansenostáticos/uso terapêutico
Hanseníase/classificação
Hanseníase/diagnóstico
Hanseníase/tratamento farmacológico
Hanseníase/epidemiologia
Hanseníase/microbiologia
Mycobacterium leprae/imunologia
Mycobacterium leprae/isolamento & purificação
Mycobacterium leprae/fisiologia
Testes Sorológicos/métodos
Pele/microbiologia
Pele/patologia
Especificidade da Espécie
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Antigens, Bacterial); 0 (BCG Vaccine); 0 (Bacterial Vaccines); 0 (Glycolipids); 0 (Leprostatic Agents); 0 (phenolic glycolipid I, Mycobacterium leprae); 11006-67-0 (Lepromin)
[Em] Mês de entrada:1407
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130723
[St] Status:MEDLINE


  3 / 479 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23741880
[Au] Autor:Shetty VP; Mistry NF; Wakade AV; Ghate SD; Capadia GD; Pai VV
[Ad] Endereço:The Foundation for Medical Research, 84-A, R.G. Thadani Marg, Worli, Mumbai - 400 018, India. fmr@fmrindia.org
[Ti] Título:BCG immunotherapy as an adjunct to chemotherapy in BL-lL patients--its effect on clinical regression, reaction severity, nerve function, lepromin conversion, bacterial/antigen clearance and 'persister' M. leprae.
[So] Source:Lepr Rev;84(1):23-40, 2013 Mar.
[Is] ISSN:0305-7518
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVE: Multidrug therapy in leprosy has failed to eliminate the problem of persister bacilli. Clearance of bacterial antigens is extremely slow which could predispose to continued nerve damage even after release from treatment. In the present study the immunomodulatory efficacy of BCG vaccine administered post-MDT in BL-LL leprosy patients was investigated in depth with a view to determining if augmenting chemotherapy with immunotherapy would help in faster clearance of M. leprae/antigens, bring down the level of persisters and minimise the occurrence/severity of reaction and nerve damage. METHODS: This is a placebo-controlled study in treated BL-LL patients. The patients are matched with respect to age, sex, bacteriological index and history of reaction, stratified and allocated to the two groups. One group (Gr A) received two doses of BCG-MOSCOW (3-33 x 10(5) cells) and the other (Gr B) normal saline (0.85%), injected intra-dermally at 3 month intervals. The Primary outcomes assessed at the end of 6 months were bacterial/antigen clearance, lepromin conversion, granuloma clearance and the occurrence of persisters. The secondary outcomes were clinical regression, occurrence and severity of reaction and changes in nerve functions. MATERIAL: A total of 107 BL-LL patients comprised of 49 in Gr A and 58 in Gr B; of which 36 and 42 respectively completed the study as per protocol, and are included in the final analysis. FINDINGS: The study findings show that both the primary and the secondary out comes were comparable in the two groups. Two doses of BCG administered post-MDT (Gr A) did not significantly alter the level of persisters or help in hastening the bacterial/antigen clearance, clinical regression of lesions and granuloma clearance. Lepromin conversion rates were also comparable. While the frequency of lepra reaction/neuritis following the intervention was comparable, the severity of reactions was significantly higher in Gr A. On the positive side neural functions assessed by nerve conduction studies showed that deterioration of motor nerve conduction was significantly lower in the BCG arm. Since all patients developing moderate to severe reactions, immediately received a course of corticosteroids, it is possible that timely use of it might have helped.
[Mh] Termos MeSH primário: Vacina BCG/uso terapêutico
Antígeno de Mitsuda/imunologia
Hansenostáticos/uso terapêutico
Hanseníase/tratamento farmacológico
Hanseníase/imunologia
Mycobacterium leprae/imunologia
Tecido Nervoso/fisiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Vacina BCG/efeitos adversos
Quimioterapia Combinada
Feminino
Seres Humanos
Imunoterapia
Hanseníase/microbiologia
Masculino
Meia-Idade
Tecido Nervoso/efeitos dos fármacos
Adulto Jovem
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (BCG Vaccine); 0 (Leprostatic Agents); 11006-67-0 (Lepromin)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:130607
[Lr] Data última revisão:
130607
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130608
[St] Status:MEDLINE


  4 / 479 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23351151
[Au] Autor:Alban SM; de Moura JF; Minozzo JC; Mira MT; Soccol VT
[Ad] Endereço:Engenharia de Bioprocessos e Biotecnologia, Universidade Federal do Paraná, Curitiba 81531-990, Brasil.
[Ti] Título:Identification of mimotopes of Mycobacterium leprae as potential diagnostic reagents.
[So] Source:BMC Infect Dis;13:42, 2013 Jan 25.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: An early diagnostic test for detecting infection in leprosy is fundamental for reducing patients' sequelae. The currently used lepromin is not adequate for disease diagnosis and, so far, no antigen to be used in intradermoreaction has proved to be sensitive and specific for that purpose. Aiming at identifying new reagents to be used in skin tests, candidate antigens were investigated. METHODS: Random peptide phage display libraries were screened by using antibodies from leprosy patients in order to identify peptides as diagnostic reagents. RESULTS: Seven different phage clones were identified using purified antibodies pooled from sera of leprosy patients. When the clones were tested with serum samples by ELISA, three of them, 5A, 6A and 1B, allowed detecting a larger number of leprosy patients when compared to controls. The corresponding peptides expressed by selected phage clones were chemically synthesized. A pilot study was undertaken to assess the use of peptides in skin tests. The intradermal challenge with peptides in animals previously sensitized with Mycobacterium leprae induced a delayed-type hypersensitivity with peptide 5A (2/5) and peptide 1B (1/5). In positive controls, there was a 3/5 reactivity for lepromin and a 4/5 reactivity of the sensitized animals with soluble extract of M. leprae. CONCLUSIONS: The preliminary data suggest that may be possible to develop reagents with diagnostic potential based on peptide mimotopes selected by phage display using polyclonal human antibodies.
[Mh] Termos MeSH primário: Antígenos de Bactérias/imunologia
Hanseníase/diagnóstico
Mycobacterium leprae/imunologia
[Mh] Termos MeSH secundário: Animais
Técnicas de Visualização da Superfície Celular
Epitopos/imunologia
Feminino
Cobaias
Seres Humanos
Hipersensibilidade Tardia/imunologia
Antígeno de Mitsuda/imunologia
Biblioteca de Peptídeos
Peptídeos/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, Bacterial); 0 (Epitopes); 0 (Peptide Library); 0 (Peptides); 11006-67-0 (Lepromin)
[Em] Mês de entrada:1306
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130129
[St] Status:MEDLINE
[do] DOI:10.1186/1471-2334-13-42


  5 / 479 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23210150
[Au] Autor:Dharmendra; Loew J
[Ti] Título:The immunological skin tests in leprosy. Part II. The isolated protein antigen in relation to the classical Matsuda reaction and the early reaction to lepromin. 1942.
[So] Source:Indian J Med Res;136(3):9p following 502, 2012 Sep.
[Is] ISSN:0971-5916
[Cp] País de publicação:India
[La] Idioma:eng
[Mh] Termos MeSH primário: Antígenos de Bactérias/imunologia
Antígeno de Mitsuda/imunologia
Hanseníase/diagnóstico
Testes Cutâneos
[Mh] Termos MeSH secundário: História do Século XX
Seres Humanos
[Pt] Tipo de publicação:BIOGRAPHY; CLASSICAL ARTICLE; HISTORICAL ARTICLE; JOURNAL ARTICLE
[Ps] Nome de pessoa como assunto:Dharmendra; Loew J
[Nm] Nome de substância:
0 (Antigens, Bacterial); 11006-67-0 (Lepromin)
[Em] Mês de entrada:1305
[Cu] Atualização por classe:121204
[Lr] Data última revisão:
121204
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121206
[St] Status:MEDLINE


  6 / 479 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:22855766
[Au] Autor:Walsh GP; Dela Cruz EC; Abalos RM; Tan EV; Fajardo TT; Villahermosa LG; Cellona RV; Balagon MV; White VA; Saunderson PR; Walsh DS
[Ad] Endereço:Leonard Wood Memorial, Cebu Leprosy and Tuberculosis Research Foundation, Cebu, Philippines.
[Ti] Título:Limited susceptibility of cynomolgus monkeys (Macaca fascicularis) to leprosy after experimental administration of Mycobacterium leprae.
[So] Source:Am J Trop Med Hyg;87(2):327-36, 2012 Aug.
[Is] ISSN:1476-1645
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cynomolgus monkeys are a useful model for human tuberculosis, but susceptibility to M. leprae is unknown. A cynomolgus model of leprosy could increase understanding of pathogenesis-importantly, neuritis and nerve-damaging reactions. We administered viable Mycobacterium leprae to 24 cynomolgus monkeys by three routes, with a median follow-up period of 6 years (range = 1-19 years) involving biopsies, nasal smears, antiphenolic glycolipid-1 (PGL-1) antibody serology, and lepromin skin testing. Most developed evanescent papules at intradermal M. leprae inoculation sites that, on biopsy, showed a robust cellular immune response akin to a lepromin skin test reaction; many produced PGL-1 antibodies. At necropsy, four monkeys, without cutaneous or gross neurological signs of leprosy but with elevated PGL-1 antibodies, including three with nasal smears (+) for acid fast bacilli (AFB), showed histological features, including AFB, suggestive of leprosy at several sites. Overall, however, cynomolgus monkeys seem minimally susceptible to leprosy after experimental M. leprae administration.
[Mh] Termos MeSH primário: Hanseníase/imunologia
Macaca fascicularis
Doenças dos Macacos/microbiologia
Mycobacterium leprae/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Antibacterianos/sangue
Antígenos de Bactérias/imunologia
Biópsia/veterinária
Modelos Animais de Doenças
Feminino
Glicolipídeos/imunologia
Histocitoquímica/veterinária
Antígeno de Mitsuda
Hanseníase/microbiologia
Masculino
Doenças dos Macacos/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Antigens, Bacterial); 0 (Glycolipids); 0 (phenolic glycolipid I, Mycobacterium leprae); 11006-67-0 (Lepromin)
[Em] Mês de entrada:1212
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:120803
[St] Status:MEDLINE
[do] DOI:10.4269/ajtmh.2012.11-0780


  7 / 479 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:19743617
[Au] Autor:Alban SM; Sella SR; Miranda RN; Mira MT; Soccol VT
[Ad] Endereço:Federal University of Paraná, 81531-990 Curitiba, PR, Brazil.
[Ti] Título:PCR-restriction fragment length polymorphism analysis as a tool for Mycobacterium species identification in lepromas for lepromin production.
[So] Source:Lepr Rev;80(2):129-42, 2009 Jun.
[Is] ISSN:0305-7518
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The aim of the present work was to standardise a PCR-Restriction Fragment Length Polymorphism analysis (PRA) as a tool to detect the mycobacteriologic composition of lepromas from leprosy patients used in the production of lepromin to improve the quality of the Mitsuda test. DESIGN: PCR-Restriction Fragment Length Polymorphism analysis using hsp65 and rpoB genes were applied to 11 reference strains of mycobacteria, including M. leprae, and the obtained PRA profiles were compared to mycobacteria in clinical specimens. RESULTS: Out of the biopsies studied, 522% had DNA fragment amplified for both genes (hsp65 and rpoB) for M. leprae. However, other Mycobacterium species were observed in samples of lepromatous leprosy patients. Here we discussed the importance of mycobacteria identification in the antigen of Mitsuda production to be used in the evaluation of leprosy. CONCLUSIONS: Our results suggest that the use of the molecular approach for sample selection can contribute to an improvement in the quality of produced lepromin.
[Mh] Termos MeSH primário: Impressões Digitais de DNA/métodos
Antígeno de Mitsuda/isolamento & purificação
Hanseníase/microbiologia
Mycobacterium leprae/classificação
Reação em Cadeia da Polimerase/métodos
Polimorfismo de Fragmento de Restrição
[Mh] Termos MeSH secundário: Proteínas de Bactérias/genética
Técnicas de Tipagem Bacteriana/métodos
Técnicas de Tipagem Bacteriana/normas
Chaperonina 60
Chaperoninas/genética
Análise por Conglomerados
Impressões Digitais de DNA/normas
RNA Polimerases Dirigidas por DNA/genética
Genótipo
Seres Humanos
Hanseníase/patologia
Mycobacterium leprae/genética
Mycobacterium leprae/isolamento & purificação
Reação em Cadeia da Polimerase/normas
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Chaperonin 60); 0 (heat-shock protein 65, Mycobacterium); 11006-67-0 (Lepromin); EC 2.7.7.6 (DNA-Directed RNA Polymerases); EC 2.7.7.6 (RNA polymerase beta subunit); EC 3.6.1.- (Chaperonins)
[Em] Mês de entrada:0909
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090912
[St] Status:MEDLINE


  8 / 479 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19703581
[Au] Autor:Mitra DK; Joshi B; Dinda AK; Rai AK; Girdhar BK; Katoch K; Bindra MS; Sengupta U
[Ad] Endereço:Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. salilmitra1@yahoo.com
[Ti] Título:Induction of lepromin reactivity in cured lepromatous leprosy patients: impaired chemokine response dissociates protective immunity from delayed type hypersensitivity.
[So] Source:Microbes Infect;11(14-15):1122-30, 2009 Dec.
[Is] ISSN:1769-714X
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Delayed Type Hypersensitivity (DTH) and protective immunity are thought to be tightly linked. Remarkable similarity exists between their cellular and immune mechanisms. However, their dissociation is also well known. Here we investigate the immunological mechanisms relevant for their dissociation in a group of non-relapsing cured lepromatous leprosy (CLL) patients. In these patients, using lepromin reaction as a model system of DTH we report critical role of tissue chemokine response in synchronous manifestation of these linked phenomena. Results indicate elevation of the threshold of tissue chemokine induction thus dissociating DTH from protective immunity in lepromin -ive CLL patients. We also show that the DTH anergy in these subjects is not an absolute one but depends on the strength of the stimulus. Our data provide insights into the intricate relationship between DTH and immunity and highlight the persistent presence of effector immune mechanisms involving these two pathways in apparently unresponsive lepromatous leprosy patients.
[Mh] Termos MeSH primário: Quimiocinas/imunologia
Hipersensibilidade Tardia/imunologia
Antígeno de Mitsuda/imunologia
Hanseníase Virchowiana/imunologia
Linfócitos T/imunologia
[Mh] Termos MeSH secundário: Quimiocinas/metabolismo
Seres Humanos
Imunidade/imunologia
Hanseníase Virchowiana/microbiologia
Ativação Linfocitária
Mycobacterium leprae/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chemokines); 11006-67-0 (Lepromin)
[Em] Mês de entrada:1002
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090826
[St] Status:MEDLINE
[do] DOI:10.1016/j.micinf.2009.08.006


  9 / 479 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:18660985
[Au] Autor:Cardona-Castro N; Beltrán-Alzate JC; Manrique-Hernández R
[Ad] Endereço:Instituto Colombiano de Medicina Tropical, Universidad CES, Sabaneta, Antioquia, Colombia. ncardona@ces.edu.co
[Ti] Título:Survey to identify Mycobacterium leprae-infected household contacts of patients from prevalent regions of leprosy in Colombia.
[So] Source:Mem Inst Oswaldo Cruz;103(4):332-6, 2008 Jun.
[Is] ISSN:1678-8060
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Leprosy in Colombia is in the post-elimination phase; nevertheless, there are regions of this country where the incidence is still around 3-4/100,000. Early detection of leprosy patients is a priority for achieving control and elimination of leprosy; however, the clinical exam is not very sensitive and thus, the majority of patients are diagnosed only when they demonstrate lesions, and damage to the nerves and skin has already occurred. The goal of the present study was to identify Mycobacterium leprae infection and immune responses in household contacts (HHC) of leprosy patients from three prevalent regions of Colombia. Clinical examination, the Mitsuda test, evaluation of IgM anti-PGL-I in the serum, the bacillar index (BI), and polymerase chain reaction (PCR) from nasal swabs (NS) were performed for 402 HHC of 104 leprosy patients during a cross-sectional survey. Positive titers for IgM anti-PGL1 were found for 54 HHC, and PCR-positive NS for 22. The Mitsuda reaction was negative for 38 HHC, although three were positive for IgM anti-PGL-1 titers. The data document that leprosy transmission among HHC is still occurring in a non-endemic country.
[Mh] Termos MeSH primário: Antígenos de Bactérias/sangue
Busca de Comunicante
Glicolipídeos/sangue
Imunoglobulina G/sangue
Hanseníase/diagnóstico
Mycobacterium leprae/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Criança
Colômbia/epidemiologia
Estudos Transversais
Ensaio de Imunoadsorção Enzimática
Feminino
Inquéritos Epidemiológicos
Seres Humanos
Testes Intradérmicos
Antígeno de Mitsuda
Hanseníase/epidemiologia
Hanseníase/transmissão
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, Bacterial); 0 (Glycolipids); 0 (Immunoglobulin G); 0 (phenolic glycolipid I, Mycobacterium leprae); 11006-67-0 (Lepromin)
[Em] Mês de entrada:0812
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080729
[St] Status:MEDLINE


  10 / 479 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:16997792
[Au] Autor:Tadesse A; Abebe M; Bizuneh E; Mulugeta W; Aseffa A; Shannon EJ
[Ad] Endereço:Armauer Hansen Research Institute, Addis Ababa, Ethiopia. Azeb.tadesse@mssm.edu
[Ti] Título:Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction.
[So] Source:Immunopharmacol Immunotoxicol;28(3):431-41, 2006.
[Is] ISSN:0892-3973
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Hypersensitivity reactions called reversal reaction (RR) and erythema nodosum leprosum (ENL) occur in leprosy. They are characterized by an increase in tumor necrosis factor-alpha (TNF-alpha). Thalidomide is an effective treatment for ENL but not RR. Its effectiveness in ENL is attributed to inhibition of TNF-alpha, and this does not explain its failure to treat RR. We assessed thalidomide's effect on TNF-alpha in RR. Mononuclear cells from RR and non-RR patients and healthy individuals were treated with thalidomide and M.leprae (AFB), a cytosol fraction of M. leprae or Dharmendra lepromin. Thalidomide suppressed TNF-alpha, but when some RR patients' cells were stimulated with AFB, it enhanced TNF-alpha.
[Mh] Termos MeSH primário: Leucócitos Mononucleares/efeitos dos fármacos
RNA Mensageiro/metabolismo
Talidomida/farmacologia
Fator de Necrose Tumoral alfa/biossíntese
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Antígenos de Bactérias/imunologia
Antígenos de Bactérias/farmacologia
Proliferação Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Células Cultivadas
Eritema Nodoso/tratamento farmacológico
Eritema Nodoso/etiologia
Eritema Nodoso/imunologia
Feminino
Seres Humanos
Antígeno de Mitsuda/imunologia
Antígeno de Mitsuda/farmacologia
Hanseníase/sangue
Hanseníase/complicações
Hanseníase/patologia
Leucócitos Mononucleares/citologia
Leucócitos Mononucleares/metabolismo
Ativação Linfocitária/efeitos dos fármacos
Masculino
Meia-Idade
Mycobacterium leprae/imunologia
Fito-Hemaglutininas/farmacologia
RNA Mensageiro/genética
Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos
Fator de Necrose Tumoral alfa/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, Bacterial); 0 (Phytohemagglutinins); 0 (RNA, Messenger); 0 (Tumor Necrosis Factor-alpha); 11006-67-0 (Lepromin); 4Z8R6ORS6L (Thalidomide)
[Em] Mês de entrada:0701
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060926
[St] Status:MEDLINE



página 1 de 48 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde